This provides a new method for endocrine therapy of breast cancer patients; that is, ACK1 inhibitor AIM-100 or dasatinib inhibits ACK1 signal to alleviate the upregulation of drug resistance by HOXA1 in breast cancer patients [5]. This evidence concerns the gene HOXA1 and breast cancer.